It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RYLPF’s FA Score shows that 1 FA rating(s) are green whileSARTF’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RYLPF’s TA Score shows that 4 TA indicator(s) are bullish while SARTF’s TA Score has 4 bullish TA indicator(s).
RYLPF (@Medical/Nursing Services) experienced а -4.15% price change this week, while SARTF (@Pharmaceuticals: Other) price change was 0.00% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.03%. For the same industry, the average monthly price growth was +0.41%, and the average quarterly price growth was +3.73%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +1.86%. For the same industry, the average monthly price growth was -3.35%, and the average quarterly price growth was +2.88%.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+1.86% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
RYLPF | SARTF | RYLPF / SARTF | |
Capitalization | 25.5B | 13.3B | 192% |
EBITDA | 2.41B | 844M | 286% |
Gain YTD | 6.289 | 0.144 | 4,367% |
P/E Ratio | 143.84 | 105.35 | 137% |
Revenue | 17.9B | 3.47B | 516% |
Total Cash | 1.82B | 872M | 209% |
Total Debt | 8.43B | 4.66B | 181% |
RYLPF | SARTF | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 48 Fair valued | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 90 | 86 | |
PRICE GROWTH RATING 1..100 | 50 | 83 | |
P/E GROWTH RATING 1..100 | 13 | 91 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RYLPF's Valuation (48) in the null industry is in the same range as SARTF (78). This means that RYLPF’s stock grew similarly to SARTF’s over the last 12 months.
RYLPF's Profit vs Risk Rating (100) in the null industry is in the same range as SARTF (100). This means that RYLPF’s stock grew similarly to SARTF’s over the last 12 months.
SARTF's SMR Rating (86) in the null industry is in the same range as RYLPF (90). This means that SARTF’s stock grew similarly to RYLPF’s over the last 12 months.
RYLPF's Price Growth Rating (50) in the null industry is somewhat better than the same rating for SARTF (83). This means that RYLPF’s stock grew somewhat faster than SARTF’s over the last 12 months.
RYLPF's P/E Growth Rating (13) in the null industry is significantly better than the same rating for SARTF (91). This means that RYLPF’s stock grew significantly faster than SARTF’s over the last 12 months.
RYLPF | SARTF | |
---|---|---|
RSI ODDS (%) | 4 days ago67% | 4 days ago50% |
Stochastic ODDS (%) | 4 days ago68% | 4 days ago66% |
Momentum ODDS (%) | 4 days ago59% | 4 days ago51% |
MACD ODDS (%) | 4 days ago49% | 4 days ago70% |
TrendWeek ODDS (%) | 4 days ago59% | 4 days ago55% |
TrendMonth ODDS (%) | 4 days ago54% | 4 days ago69% |
Advances ODDS (%) | N/A | N/A |
Declines ODDS (%) | N/A | N/A |
BollingerBands ODDS (%) | 4 days ago62% | 4 days ago51% |
Aroon ODDS (%) | 4 days ago44% | 4 days ago78% |
A.I.dvisor indicates that over the last year, RYLPF has been loosely correlated with MTD. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if RYLPF jumps, then MTD could also see price increases.
Ticker / NAME | Correlation To RYLPF | 1D Price Change % | ||
---|---|---|---|---|
RYLPF | 100% | N/A | ||
MTD - RYLPF | 38% Loosely correlated | +1.54% | ||
CDNA - RYLPF | 28% Poorly correlated | -0.83% | ||
MBGNF - RYLPF | 24% Poorly correlated | N/A | ||
SRTS - RYLPF | 23% Poorly correlated | -35.23% | ||
WRBY - RYLPF | 21% Poorly correlated | -0.64% | ||
More |
A.I.dvisor indicates that over the last year, SARTF has been loosely correlated with SDMHF. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if SARTF jumps, then SDMHF could also see price increases.
Ticker / NAME | Correlation To SARTF | 1D Price Change % | ||
---|---|---|---|---|
SARTF | 100% | N/A | ||
SDMHF - SARTF | 39% Loosely correlated | +2.48% | ||
SOAGY - SARTF | 27% Poorly correlated | +1.10% | ||
EXAS - SARTF | 21% Poorly correlated | -5.03% | ||
RSMDF - SARTF | 16% Poorly correlated | N/A | ||
RYLPF - SARTF | 9% Poorly correlated | N/A | ||
More |